KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial.

Juying Qian, Xuelian Zhang, Jiyan Chen, Chunhua Ding, Ping Yang, Li Qing, Yan Liu, Si Si Chen, Junbo Ge

Adv Ther 43(3) 1187-1198

PMID41553712
PMCIDPMC12999713
DOI10.1007/s12325-025-03429-8
发表日期2026-01-19
入排依据:未发现恶性肿瘤人群证据。
已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig. 1:森林图/亚组分析图。
摘要

摘要

INTRODUCTION: Combining ezetimibe (EZ) and statins is recommended for the treatment of elevated low-density lipoprotein-cholesterol (LDL-C). This subgroup analysis evaluated the efficacy of fixed-dose combination (FDC) therapy with EZ and atorvastatin (AS) versus AS monotherapy on attaining LDL-C goals in Chinese patients with very high risk of atherosclerotic cardiovascular disease (ASCVD) grouped by ASCVD risk, age, and sex. METHODS: Data from the phase III, randomized, double-blind study (NCT03768427) compared EZ10/AS10 mg FDC versus AS20 mg (cohort A), and EZ10/AS20 mg FDC versus AS40 mg monotherapy (cohort B) in Chinese patients with uncontrolled hypercholesterolemia. Proportions of patients attaining 2016 Chinese guideline-recommended LDL-C goals (low/medium risk [< 130 mg/dL], high risk [< 100 mg/dL], very high risk [< 70 mg/dL]) were assessed at weeks 6 and 12. Subgroup analyses by ASCVD risk, age (< 65 and ≥ 65 years), and sex were conducted. RESULTS: LDL-C goal attainment was significantly higher with FDCs versus AS monotherapy at week 12 (cohort A: 62.7% vs. 35.1%, P = 0.0009; cohort B: 67.5% vs. 31.0%, P < 0.0001). A greater proportion of patients with very high ASCVD risk attained LDL-C goals with FDCs versus AS monotherapy at week 12 (cohort A: 62.3% vs. 33.9%; cohort B: 69.1% vs. 29.5%). LDL-C goal attainment was higher with FDCs versus individual doses of AS at weeks 6 and 12 in both cohorts, regardless of age or sex. CONCLUSION: FDCs significantly improved LDL-C goal attainment compared to AS monotherapy in patients with very high ASCVD risk. In the subgroups by age and sex, a higher proportion of patients with uncontrolled hypercholesterolemia attained their LDL-C goals. TRIAL REGISTRY: Trial registration number NCT03768427.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 LDL-C goal attainment at week 12 post-treatment by subgroup. a Age subgroup (< 65 years and ≥ 65 years). b Sex subgroup (male patients and female patients). AS20 atorvastatin 20 mg, AS40 atorvastatin 40 mg, CI confidence interval, Cohort A atorvastatin 10 mg during the run-in period, Cohort B atorvastatin 20 mg during the run-in period, EZ10/AS10 mg ezetimibe 10/atorvastatin 10 mg, EZ10/AS20 mg ezetimibe 10/atorvastatin 20 mg, LDL-C low density lipoprotein-cholesterol, RD risk difference
非 KM Figure